{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:19:02Z","timestamp":1772752742759,"version":"3.50.1"},"reference-count":61,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,10,13]],"date-time":"2006-10-13T00:00:00Z","timestamp":1160697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This study examined the ability of the semi\u2010synthetic vinca alkaloid, Vinorelbine\/Navelbine, to cause apoptotic death in freshly obtained primary leukaemia cells from 53 patients with haematological malignancies, including 22 patients with acute lymphoblastic leukaemia (ALL), 24 patients with chronic lymphocytic leukaemia (CLL), three patients with chronic myeloid leukaemia in blast crisis (CML\u2010BC) and four patients with acute myeloid leukaemia (AML). Vinorelbine caused apoptosis in primary leukaemia cells from 42 (79%) of these leukaemia patients. Objective responses, including complete remission (CR) and CR with incomplete haematological recovery, were achieved in 12 of 17 (71%) patients with aggressive and therapy\u2010refractory leukaemias, including five of nine patients with relapsed ALL, three of three patients with CML\u2010BC and four of five patients with rapidly progressive CLL, who were treated with a vinorelbine\u2010based salvage chemotherapy regimen. Drug sensitivity profiling of multidrug\u2010resistant primary cancer cells using apoptosis assays revealed a significant association between Vinorelbine sensitivity <jats:italic>in vitro<\/jats:italic> and the likelihood of an objective clinical response to Vinorelbine\u2010based chemotherapy. Vinorelbine\u2010sensitivity testing of primary leukaemia cells might help tailor Vinorelbine\u2010based salvage regimens to those patients who are most likely to respond.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2006.06338.x","type":"journal-article","created":{"date-parts":[[2006,10,18]],"date-time":"2006-10-18T10:34:10Z","timestamp":1161167650000},"page":"500-508","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Vinorelbine\u2010based salvage chemotherapy for therapy\u2010refractory aggressive leukaemias"],"prefix":"10.1111","volume":"135","author":[{"given":"Fatih M.","family":"Uckun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanda","family":"Morar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjive","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,10,16]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-1-21"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.863"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-9002"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.053"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403538"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.012"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04584.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401963"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.moh.0000208468.40991.f2"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207558"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500312295"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-000-0015-z"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1031"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009043332763"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05773.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000181403.75460.c7"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1203"},{"key":"e_1_2_5_19_1","first-page":"540","article-title":"New approaches to acute lymphoblastic leukemia in adults: where do we go?","volume":"27","author":"Hoelzer D.","year":"2000","journal-title":"Seminars in Oncology"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1541"},{"key":"e_1_2_5_21_1","first-page":"676","article-title":"Therapeutic activity of basic bisepoxides in murine leukemia and other transplantable mouse neoplasms","volume":"16","author":"Johnson I.S.","year":"1960","journal-title":"Acta - Unio Internationalis Contra Cancrum"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00625-6"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402489"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206945"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20947"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403097"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.015"},{"issue":"1","key":"e_1_2_5_29_1","first-page":"S127","article-title":"The U.S. trials in adult acute lymphoblastic leukemia","volume":"83","author":"Larson R.A.","year":"2004","journal-title":"Annals of Hematology"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02216.x"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.116"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(85)90186-7"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi243"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1082-9"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05544.x"},{"key":"e_1_2_5_36_1","first-page":"1094","article-title":"Bis (4,7\u2010dimethyl\u20101,10\u2010phenanthroline) sulfatooxovanadium (I.V.) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity","volume":"7","author":"Narla R.K.","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109060353"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00482.x"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.445"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009065828"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402526"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.050"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809057599"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568011024606361"},{"key":"e_1_2_5_46_1","first-page":"2945","volume-title":"Acute Lymphoblastic Leukaemia in Children","author":"Trigg M.E.","year":"1997"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.016"},{"key":"e_1_2_5_48_1","first-page":"14","article-title":"Treating chronic leukemias","volume":"16","author":"Uckun F.M.","year":"2002","journal-title":"Minnesota Physician"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.19.9005"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.273.5278.1096"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2214"},{"key":"e_1_2_5_52_1","first-page":"28","article-title":"Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group","volume":"90","author":"Uckun F.M.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_5_53_1","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood.V89.10.3769","article-title":"Cellular expression of antiapoptotic BCL\u20102 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study","volume":"89","author":"Uckun F.M.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<2030::AID-CNCR21>3.0.CO;2-Q"},{"key":"e_1_2_5_55_1","first-page":"735","article-title":"Biology and treatment of childhood T\u2010lineage acute lymphoblastic leukemia","volume":"91","author":"Uckun F.M.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909093730"},{"key":"e_1_2_5_57_1","first-page":"252","article-title":"SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity","volume":"1","author":"Uckun F.M.","year":"2000","journal-title":"Current Opinion in Investigational Drugs"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(00)00148-7"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009013334287"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401960"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.014"},{"key":"e_1_2_5_62_1","first-page":"287","article-title":"Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non\u2010Hodgkin's lymphoma","volume":"86","author":"Zinzani P.L.","year":"2001","journal-title":"Haematologica"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2006.06338.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2006.06338.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T14:45:44Z","timestamp":1697381144000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2006.06338.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,16]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1111\/j.1365-2141.2006.06338.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06338.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,16]]},"assertion":[{"value":"2006-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}